Welcome to our dedicated page for ICON news (Ticker: ICLR), a resource for investors and traders seeking the latest updates and insights on ICON stock.
ICON plc reports developments for a global contract research organization that provides outsourced clinical development services to pharmaceutical and biotechnology companies. Its news commonly covers operating and financial results, clinical trial management activity, net business wins, revenue guidance, and service areas such as patient recruitment, data analytics, laboratory services and regulatory consulting.
Company updates also address partnerships that connect clinical trial technology with research-site systems, expansion of the Accellacare Site Network in therapeutic areas including oncology, and governance or accounting-control matters tied to revenue recognition and financial reporting.
ICON (NASDAQ: ICLR) selected Microsoft as a preferred technology partner to advance its three‑year digital innovation and AI plan. The collaboration includes enterprise‑wide deployment of Microsoft 365 Copilot and Azure‑based cloud, data and AI infrastructure to scale Orbis, ICON’s secure agentic AI platform.
The partnership targets four areas across the clinical trial lifecycle: AI‑enabled study design, operational execution, patient and site engagement, and real‑time decision‑making. It aligns with ICON’s AI strategy focus on a unified intelligence layer, company‑wide productivity gains, and domain‑specific agents embedded directly into clinical workflows.
ICON (NASDAQ: ICLR) will release its first quarter 2026 financial results after market close on Tuesday, June 23, 2026. Management will host a conference call and webcast to discuss results and performance on Wednesday, June 24, 2026 at 8:00am ET.
Event updates, webcast links, and a replay (available about one hour after the call) will be accessible in the Investor section of the company website under Events.
ICON (NASDAQ: ICLR) reported Q4 2025 revenue of $2,112.5M and full-year 2025 revenue of $8,251.3M, with adjusted EBITDA of $327.1M in Q4 and $1,530.7M for 2025.
The Audit Committee completed its investigation, leading to small revenue restatements for 2023–2024, identified material control weaknesses, updated backlog policies and issued 2026 guidance of $7,850–$8,150M revenue and $10.00–$11.00 adjusted EPS.
ICON (NASDAQ: ICLR) will release fourth quarter and full year 2025 results after market close on May 27, 2026, followed by a conference call on May 28, 2026 at 8:00 a.m. ET. ICON also received a Nasdaq Listing Rule 5250(c)(1) deficiency notice due to its pending 2025 Form 20-F filing.
The notice does not immediately affect listing or trading. ICON has 60 days to submit a compliance plan and expects to regain compliance by filing the Form 20-F before the earnings call.
ICON (NASDAQ: ICLR) is expanding US early phase research with a new 69.5K square-foot Clinical Research Unit in San Antonio, Texas, plus satellite outpatient clinics in Houston, Texas and Lawrence, Kansas.
The integrated San Antonio facility combines clinic, pharmacy and laboratory to support first-in-human and Phase I studies, enhance dosing speed, enable real-time protocol changes, and improve participant safety and experience while extending ICON’s global Phase I network.
ICON (NASDAQ: ICLR) announced its Audit Committee completed an investigation into accounting practices and will restate results for 2023, 2024 and the first nine months of 2025. Revenue was overstated in 2023 and 2024, with each year’s overstatement below the previously disclosed 2% upper limit; 2025 impact was smaller. The company expects the audit and final financial statements to be completed in the coming weeks and will file its Annual Report on Form 20-F disclosing material weaknesses and remediation plans.
ICON (NASDAQ: ICLR) and Advarra announced a definitive partnership to create a “research-ready,” connected site network model that integrates ICON’s clinical trial technology with Advarra’s site CTMS, eISF, eSource and Study Collaboration.
The partnership covers Advarra systems used by >50,000 investigators, 90 of the top 125 academic medical centers, and 90% of NCI‑Designated Cancer Centers, and will leverage Braid™ analytics. Advarra reports managing >$4B trial invoice value, >3M patient visits, and >2M electronic documents last year. Expected benefits include reduced administrative friction, faster study startup, improved site selection, and broader trial access.
Summary not available.
Summary not available.
ICON (NASDAQ: ICLR) expanded oncology research within its Accellacare Site Network by opening the Brian Moran Cancer Institute at Duly Health and Care in Illinois on January 27, 2026. The institute adds clinical capacity with 14 medical oncologists, 3 radiation oncologists, and 9 fellowship-trained surgical specialists across urologic, breast, colorectal, endocrine and general surgical oncology.
This partnership builds on existing Accellacare oncology capabilities at the McFarland Clinic in Ames, Iowa, and aims to strengthen patient recruitment and broaden access to oncology clinical trials for sponsors and patients.